| Rate of Treg cell inhibition by Sunitinib | 0.227 | day−1 | [45] |
| Rate of Treg cell depletion from chemotherapy toxicity |
| day−1 | [45] |
| Determines the scope of influence of KRAS-mutant tumor cells Tcp in making tumor cells resistant to chemotherapy and in reducing the sensitizing role of Cetuximab and Panitumumab to chemotherapy |
| unitless | [25] |
| Efficacy of Sunitinib in inhibiting the immunosuppressive activity of Tregs | 50.02 | L mg−1 | [45] |
| Chemotherapy toxicity on Tregs |
| L mg−1 | [32] |
| Rate of excretion and elimination of Sunitinib | 0.277 | day−1 | [45] |
| Growth rate of mutant tumor cells (colorectal cancer) |
| day−1 | [32] |
| Maximum mutation rate of wild-type tumor cells |
| day−1 | [55] |
| Concentration of Irinotecan chemotherapy that leads to a half-maximal rate of mutation of wild-type tumor cells Tw into irinotecan-resistant tumor cells Ti |
| mg L−1 | Est. |
| Efficacy of the second type of chemotherapy drug of killing irinotecan-resistant tumor cells |
| L mg−1 | [32] |
| Rate of excretion and elimination of the hypothetical chemotherapy drug |
| day−1 | [32] |
| Degradation rate of anti-TGF-beta (Fresolimumab) | 0.033 | day−1 | Est. from [56] |
| Rate of loss of free TGF-β due to binding with anti-TGF-β | 100 | L mg−1 day−1 | Est. from [56] |
| Rate of loss of free anti-TGF-β due to binding with TGF-β |
| L IU−1 day−1 | Est. from [56] |
| Differentiation rate of M0 macrophages into an M1 or M2 macrophage |
| day−1 | Est. from [31] |